siRNA and isRNA: two edges of one sword - PubMed (original) (raw)
Review
siRNA and isRNA: two edges of one sword
Martin Schlee et al. Mol Ther. 2006 Oct.
Free article
Abstract
RNA interference mediated by small interfering RNAs (siRNA) has emerged as a powerful tool to target specific knockdown of gene expression in cell culture. siRNA is now the gold standard technique to study gene function, and expectations for the development of new target-specific drugs are high. In addition to the gene-silencing activity of siRNA, a number of recent studies have pointed to immunological effects of siRNAs, including the induction of proinflammatory cytokines and type I interferon. There is good evidence that gene silencing and immunostimulation are two independent functional characteristics of RNA oligonucleotides. Immunorecognition of RNA depends on certain molecular features such as length, double- versus single-strand configuration, sequence motifs, and nucleoside modifications such as triphosphate residues. RNA-sensing immunoreceptors include three members of the Toll-like receptor (TLR) family (TLR3, TLR7, TLR8) and cytosolic RNA-binding proteins like PKR and the helicases RIG-I and Mda5. Detection of RNA molecules occurs during viral infection and triggers antiviral innate defense mechanisms including the induction of type I interferons (IFN-alpha, IFN-beta) and downregulation of gene expression. Type I interferon induction by synthetic siRNAs requires TLR7 and is sequence dependent, similar to the detection of CpG motifs in DNA by TLR9. Identification of the exact molecular mechanisms of immunorecognition of RNA will allow the development of methods to avoid immunostimulation of siRNA and the design of potent immunostimulatory RNA (isRNA) oligonucleotides, depending on the aim. Furthermore, the combination of both gene-silencing and immunostimulation in one RNA molecule may lead to novel drugs that use both functional activities of RNA as two edges of one sword for effective treatment of viral infection and cancer.
Similar articles
- Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.
Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G. Hornung V, et al. Nat Med. 2005 Mar;11(3):263-70. doi: 10.1038/nm1191. Epub 2005 Feb 20. Nat Med. 2005. PMID: 15723075 - Astrocytes are very sensitive to develop innate immune responses to lipid-carried short interfering RNA.
Gorina R, Santalucia T, Petegnief V, Ejarque-Ortiz A, Saura J, Planas AM. Gorina R, et al. Glia. 2009 Jan 1;57(1):93-107. doi: 10.1002/glia.20738. Glia. 2009. PMID: 18709661 - Signal regulatory protein alpha negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction.
Dong LW, Kong XN, Yan HX, Yu LX, Chen L, Yang W, Liu Q, Huang DD, Wu MC, Wang HY. Dong LW, et al. Mol Immunol. 2008 Jun;45(11):3025-35. doi: 10.1016/j.molimm.2008.03.012. Epub 2008 May 8. Mol Immunol. 2008. PMID: 18471880 - Deciphering the code of innate immunity recognition of siRNAs.
Sioud M. Sioud M. Methods Mol Biol. 2009;487:41-59. doi: 10.1007/978-1-60327-547-7_2. Methods Mol Biol. 2009. PMID: 19301641 Review. - Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing.
Seya T, Matsumoto M, Ebihara T, Oshiumi H. Seya T, et al. Immunol Rev. 2009 Jan;227(1):44-53. doi: 10.1111/j.1600-065X.2008.00723.x. Immunol Rev. 2009. PMID: 19120474 Review.
Cited by
- Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges.
Kang H, Ga YJ, Kim SH, Cho YH, Kim JW, Kim C, Yeh JY. Kang H, et al. J Biomed Sci. 2023 Oct 16;30(1):88. doi: 10.1186/s12929-023-00981-9. J Biomed Sci. 2023. PMID: 37845731 Free PMC article. Review. - Where should siRNAs go: applicable organs for siRNA drugs.
Ahn I, Kang CS, Han J. Ahn I, et al. Exp Mol Med. 2023 Jul;55(7):1283-1292. doi: 10.1038/s12276-023-00998-y. Epub 2023 Jul 10. Exp Mol Med. 2023. PMID: 37430086 Free PMC article. Review. - MiR-34a induces myofibroblast differentiation from renal fibroblasts.
Saito S, Ohno SI, Harada Y, Kanno Y, Kuroda M. Saito S, et al. Clin Exp Nephrol. 2023 May;27(5):411-418. doi: 10.1007/s10157-023-02329-x. Epub 2023 Feb 18. Clin Exp Nephrol. 2023. PMID: 36808381 - siRNA and targeted delivery systems in breast cancer therapy.
Mirzaei S, Paskeh MDA, Entezari M, Bidooki SH, Ghaleh VJ, Rezaei S, Hejazi ES, Kakavand A, Behroozaghdam M, Movafagh A, Taheriazam A, Hashemi M, Samarghandian S. Mirzaei S, et al. Clin Transl Oncol. 2023 May;25(5):1167-1188. doi: 10.1007/s12094-022-03043-y. Epub 2022 Dec 23. Clin Transl Oncol. 2023. PMID: 36562927 Review. - Chemical Modifications Influence the Number of siRNA Molecules Adsorbed on Gold Nanoparticles and the Efficiency of Downregulation of a Target Protein.
Epanchintseva AV, Poletaeva JE, Dome AS, Dovydenko IS, Pyshnaya IA, Ryabchikova EI. Epanchintseva AV, et al. Nanomaterials (Basel). 2022 Dec 14;12(24):4450. doi: 10.3390/nano12244450. Nanomaterials (Basel). 2022. PMID: 36558301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous